Where reported and normalized margins diverge most
Across a life-sciences and medtech cohort on one basis, the gap between reported and normalized operating margin ranges from 4.3 to 8.5 points. Becton Dickinson shows the widest — 11.8% as filed against 20.3% once acquired-intangible amortisation and restructuring are treated consistently. The gap is not a judgement about quality; it is a measure of how much of a company's reported margin depends on accounting treatment.
Put four companies on one basis and the interesting number is not the margin — it is the distance the margin travels.
On a basis that adds back acquired-intangible amortisation and restructuring, FY2025 operating margins move: Danaher 19.1% → 26.0%, Thermo Fisher 17.4% → 21.7%, Stryker 19.5% → 22.4%, Becton Dickinson 11.8% → 20.3%.
Ranked by the size of the move rather than the level, the order inverts. Becton Dickinson is last on reported margin and mid-pack on the basis; the 8.5-point gap is the largest in the cohort. Danaher and Thermo Fisher, which look furthest apart as filed, sit four points apart once treated the same way.
None of this says one company is better run. It says how much of each reported figure is a function of treatment rather than operations — and that a comp table built on reported margins was ranking accounting policy.
Every figure here is parsed from the companies’ own filings and carries its accession number and XBRL concept. The basis used is published; change a rule and these numbers change with it.